Alumis Inc. (ALMS)
NASDAQ: ALMS · IEX Real-Time Price · USD
11.94
-0.60 (-4.78%)
At close: Jul 2, 2024, 4:00 PM
12.32
+0.38 (3.18%)
After-hours: Jul 2, 2024, 5:49 PM EDT
Alumis Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
107
Market Cap
673.05M
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionALMS News
- 4 days ago - Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering - Benzinga
- 4 days ago - Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut - Reuters
- 4 days ago - Therapy developer Alumis prices U.S. IPO at about $902 mln valuation - Reuters
- 4 days ago - Alumis Announces Pricing of Initial Public Offering - GlobeNewsWire
- 8 days ago - Therapy developer Alumis seeks up to $1 bln valuation in US IPO - Reuters
- 8 days ago - Alumis eyes $300 million in proceeds in IPO - Market Watch
- 25 days ago - Alumis, a biotech focused on immune-mediated diseases, files for a $100 million IPO - Renaissance Capital
- 25 days ago - Alumis IPO Registration Document (S-1) - SEC